featured
Efficacy and Safety of Cilta-Cel in Anti–BCMA-Exposed Patients With Progressive Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Blood 2023 Jan 19;141(3)219-230, AD Cohen, MV Mateos, YC Cohen, P Rodriguez-Otero, B Paiva, NWCJ van de Donk, T Martin, A Suvannasankha, KC De Braganca, C Corsale, JM Schecter, H Varsos, W Deraedt, L Wang, M Vogel, T Roccia, X Xu, P Mistry, E Zudaire, M Akram, T Nesheiwat, L Pacaud, I Avivi, J San-MiguelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.